Glyxambi (Linagliptin, Empagliflozin)

When used together, the DPP‑4 inhibitor and SGLT2 inhibitor provide complementary glucose‑lowering effects—linagliptin primarily affects post‑prandial glucose, while empagliflozin reduces fasting glucose and promotes urinary glucose loss. This dual approach can achieve better overall glycemic control than either agent alone.

Glyxambi is prescribed for adult patients with type 2 diabetes mellitus who require additional glycemic control beyond diet, exercise, and monotherapy with other oral antidiabetic agents such as metformin.

Renal function should be evaluated before initiating Glyxambi. Empagliflozin efficacy declines with reduced kidney function, and the drug is generally not recommended in patients with severe renal impairment. Moderate impairment may be permissible with dose adjustment and close monitoring.

Common adverse events include upper respiratory tract infection symptoms, headache, nausea or abdominal discomfort, and increased frequency of urination.

Glyxambi is taken orally once daily, with or without food. Consistency in timing each day helps maintain stable drug levels.

Empagliflozin can produce modest reductions in systolic and diastolic blood pressure due to its osmotic diuretic effect. Patients on antihypertensive therapy should be monitored for additive blood‑pressure lowering.

Patients should contact their healthcare provider promptly. The provider may evaluate the infection, consider temporary discontinuation of empagliflozin, and prescribe appropriate antimicrobial therapy.

When Glyxambi is used together with insulin or insulin‑secretagogues (e.g., sulfonylureas), the risk of hypoglycemia increases. Dose adjustments of insulin may be necessary, and blood glucose should be monitored closely.

Safety data for Glyxambi in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and under close medical supervision.

Renal function should be assessed before starting therapy and periodically thereafter, especially in patients with existing kidney disease or those taking concomitant nephrotoxic medications.

Empagliflozin may lead to modest weight reduction due to caloric loss from urinary glucose excretion. Any weight change varies among individuals.